ULTIMATE: chemotherapy plus bevacizumab beyond first line
As chemotherapy in the second-line or third-line settings of NSCLC shows limited efficacy, the phase III, randomised ULTIMATE trial tested the combination of chemotherapy and bevacizumab in patients with advanced NSCLC of non-squamous histology, who had progressed after one or two lines of treatment. Prior platinum-based and pemetrexed therapies were mandatory, and prior bevacizumab was allowed. While the control patients received docetaxel every three weeks (n = 55), those in the experimental arm were treated with paclitaxel weekly plus bevacizumab every four weeks (n = 109). Treatment continued until progression or toxicity.
Weekly paclitaxel plus bevacizumab showed highly significant superiority over docetaxel monotherapy for both ORR at week 8 (22.5 % vs. 5.5 %; p = 0.006) and median PFS (5.4 vs. 3.9 months; p = 0.006). With the addition of bevacizumab, the risk of progression or death was reduced by 38 %. The PFS curves separated early on (Figure). According to the subgroup analysis, only patients with prior exposure to bevacizumab and those with performance status score of 2 did not benefit from the combined treatment. OS was similar across the two groups.
Figure: Progression-free survival with paclitaxel plus bevacizumab versus docetaxel
At the same time, the bevacizumab-based regimen showed significantly less haematological toxicity compared to docetaxel, and the patient quality of life was preserved. As the authors concluded, ULTIMATE introduces weekly paclitaxel and bevacizumab as a new second-line or third-line treatment option for NSCLC patients with non-squamous tumours.
REFERENCES
- Cortot AB et al., Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): results from the phase III study IFCT-1103 ULTIMATE. J Clin Oncol 34, 2016 (suppl; abstr 9005)
More posts
PFS improvement due to local therapy in oligometastatic NSCLC
Evidence suggests the existence of a ,limited metastatic’ NSCLC phenotype. However, the type of optimal treatment and the role of aggressive local therapy in these patients remain controversial. Gomez et al. presented the first prospective, randomised trial to address this question. Patients had stage IV disease without RECIST progression and a maximum of three metastases after front-line systemic therapy (FLST).
Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide
The randomised, multicentre, open-label, phase II RENO trial was conducted with the objective of establishing a standard chemotherapy regimen in the setting of chemo-radiotherapy of locally advanced NSCLC. A total of 134 patients with inoperable stage III NSCLC received either oral vinorelbine plus cisplatin or etoposide plus cisplatin.
ULTIMATE: chemotherapy plus bevacizumab beyond first line
As chemotherapy in the second-line or third-line settings of NSCLC shows limited efficacy, the phase III, randomised ULTIMATE trial tested the combination of chemotherapy and bevacizumab in patients with advanced NSCLC of non-squamous histology, who had progressed after one or two lines of treatment.
New approaches are raising hope for SCLC patients
Only minor progress has been made over the past 30 to 40 years in the treatment of small-cell lung cancer (SCLC), which accounts for 10 % to 15 % of lung cancer cases. SCLC is radiosensitive, but approximately 70 % of patients present with extended disease that cannot be included within one radiotherapy field. The majority of patients respond to first-line chemotherapy.
Mutational analysis: on the road to refined standards
The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional consortium for the study of driver mutations of lung adenocarcinoma. The cooperating sites enable the identification of relatively large numbers of patients with uncommon and rare alterations, facilitate the analysis of their clinical characteristics, and lay the ground for targeted therapy trials.
“The importance of first-line and second-line targeted agents is obvious”
Which parameters should be taken into consideration regarding the choice of EGFR TKIs in a lung cancer patient with an activating EGFR mutation? When EGFR mutations are diagnosed in the first-line setting, we have the luxury of having three options today. However, it is important to discriminate between the different types.
